Atrial fibrillation and congestive heart failure

Minerva Medica

Volumn 100, Issue 2, 2009, Pages 137-143

  Bourke, T ^a   Boyle, N G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrial fibrillation, therapy; Heart diseases; Heart failure

Indexed keywords

CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; PATIENT CARE; PROGNOSIS; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; HEART FAILURE; HEART RATE; HUMANS; RISK FACTORS;

EID: 67749130925     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952 (Pubitemid 28446646)
2. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91;2D-8D. Review.
3. Bourassa MG, Gurn'e O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M et al., for the Studies of Left Ventricular Dysfunction (SOLVD) investigators: Natural history and patterns of current practice in heart failure. J AmColl Cardiol 1993;22(Suppl A):14A-19A.
4. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN, for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. Circulation 1993;87(Suppl VI):VI-102-VI-110.
5. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN, for the Department of Veterans Affairs CHFSTAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998;98:2574-2579 (Pubitemid 29001197)
6. Heist EK, Ruskin JN. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog Cardiovasc Dis 2006;48:256-269 Review.
7. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: Specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002;13:399-405. (Pubitemid 34407608)
8. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512-25. (Pubitemid 27432738)
9. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and haemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204. (Pubitemid 28351062)
10. Mahoney P, Kimmel S, De Nofrio D, Wohl P, Loh E. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 1999;83:1544-1547 (Pubitemid 29250037)
11. Crijns HJGM, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, van den BergMP et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000;21:1238-1245 (Pubitemid 30487771)
12. Middlekauf HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991;84:40-48
13. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703.
14. Maggioni AP, Di Gregorio L, Gorini M, Midi P, Lucci D, Tavazzi L, on behalf of IN-CHF Investigators. Predictors of 1 year mortality in 2086 outpatients with congestive heart failure: Data from Italian network on congestive heart failure. J Am Coll Cardiol 1998:34(Suppl A):218A. Abstract.
15. Matthew J, Hunsberger S, Fleg J, McSherry F, Williford W, Yusuf S, for the Digitalis Investigation Group. Incidence, predictive factors and prognostic significance of supraventricular tachy-arrhythmias in congestive heart failure. J AmColl Cardiol 1998;34(Suppl A):218A. Abstract.
16. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Study. Circulation 2003;107:2920-2925 (Pubitemid 36736633)
17. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703.
18. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-557 (Pubitemid 40585420)
19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870 (Pubitemid 32537350)
20. Gage BF, wan Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-2292
21. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the ACC/AHA/ESC Task Force on Practice Guidelines for the Management of Patients With Atrial Fibrillatin). Circulation 2006;114:e257-354.
22. Singer DE, Albers GW, Dalen JE et al Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133(6 Suppl):546S-92S.
23. Olahansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A et al. The Atrial fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-1208 (Pubitemid 38452597)
24. Joglar JA, Acusta AP, Schusterman NH et al. Effect of carvedilol on survival and haemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of U.S Carvedilol Heart Failure Trial Program. Am Heart J 2001;142:498-501.
25. Amiodarone Trial Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congextive ehart failure: meta-analysis of individual data from 6 500 patients in randomised trials. Lancet 1997;350:1417-1424
26. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial fibrillation Investigators. N Engl J Med 2000;342:913-920
27. The AFFIRM First Antirrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation. An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003;43:20-29
28. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodelling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-61. (Pubitemid 34327924)
29. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in clogs with ventricular tachypacing induced congestive heart failure. Circulation 2001;104:2608-2614 (Pubitemid 33104801)
30. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-1383 (Pubitemid 37532555)
31. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H. Ogawa S et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007;74:75-84. (Pubitemid 46366949)
32. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 2000;101:1138-1144 (Pubitemid 30146615)
33. Valls-Bertault V, Fatemi M, Guard M, Pennec PY, Etienne Y, Blanc JJ. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junction ablation for chronic atrial fibrillation. Europace 2004;6:438-443 (Pubitemid 39117850)
34. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M. Sacher F et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-2383 (Pubitemid 40500183) (Pubitemid 40500183)
35. Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:1778-1785
36. Prasad SM, Maniar HS, Camillo CJ, Schuessler RB, Boineau JP, Sundt TM 3rd et al. The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg 2003;126:1822-1828